Loading...

MNPR MONOPAR THERAPEUTICS Management Changes 8-K Filing

MNPR

MNPR

MONOPAR THERAPEUTICS

(MNPR)

2025 8-K

Financial Results

New Data Presentation

Stock Offering Announcement

Data Presentation

Financial Statements

New Product Launches

Financial Results

Management Change

New Drug Announcement

Q3 Financial Results

License Agreement

Clinical Data Presentation

Patent Application

Clinical Trial Update

Clinical Trial Update

Nasdaq Compliance

Trial Clearance

Clinical Trial Update

Financial Results and Rever...

Clinical Trial Enrollment

Collaboration Expansion

Preclinical Data Announcement

Management Changes

Financial Results Announcement

Patent Application

Financial Results Announcement

Radiopharma Presentation

Management Changes

Product Launches

Earnings Reports

Financial Results Announcement

Press Release Update on Pha...

Financial Results Announcement

Discontinuation of Validive...

Financial Results Announcement

Expansion and Positive Results

Update on Phase 1b Trial fo...

Product Launches

External Links:

On February 28, 2025, Karthik Radhakrishnan left his role as Chief Financial Officer of Monopar Therapeutics, and Quan Vu was appointed to succeed him effective March 3, 2025, with a salary of $350,000 and stock options.

AI Assistant

MONOPAR THERAPEUTICS

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.